Copyright
©The Author(s) 2025.
World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Table 5 Baseline hematological prognostic indicators markers for patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1immunotherapy, mean ± SD
Characteristics | Stats | Normal range |
Height (cm) | 168.3 ± 8.0 | 140-190 |
Weight (kg) | 67.7 ± 12.0 | 40-100 |
ALLC (109/L) | 6.0 ± 1.9 | 3.5-9.5 |
RDW (%) | 15.2 ± 3.8 | 11.6-14.8 |
PLT (109/L) | 178.2 ± 63.7 | 125-350 |
ANC (109/L) | 4.1 ± 1.4 | 1.8-6.3 |
ALC (109/L) | 1.4 ± 0.5 | 1.1-3.2 |
AMC (109/L) | 0.4 ± 0.1 | 0.1-0.6 |
AEC (109/L) | 0.2 ± 0.2 | 0.02-0.52 |
ALB (g/L) | 41.4 ± 4.0 | 40-55 |
LDH (IU/L) | 240.0 ± 154.9 | 109-245 |
FIB (g/L) | 3.6 ± 0.7 | 2-4 |
Dimer (ng/ml) | 257.3 ± 647.3 | 0-500 |
CEA (ng/mL), n (%) | 6 (24.0%) | 0-5 |
19 (76.0%) | - | |
CA199 (IU/mL), n (%) | 13 (52.0%) | 0-37 |
12 (48.0%) | - |
- Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(21): 106939
- URL: https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i21.106939